Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service DBS & VNS cases in Florida: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 17% on average (103 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 12 | 823 | 49% |
| 2020 | 11 | 876 | 52% |
| 2021 | 16 | 1,102 | 54% |
| 2022 | 8 | 819 | 56% |
| 2023 | 10 | 877 | 58% |
| 2024 | 13 | 844 | 60% |
| 2025 from claims | – | 1,221 987–1,434 | 61% |
| 2026 forecast | – | 1,285 1,007–1,614 | 61% |
| 2027 forecast | – | 1,347 999–1,781 | 61% |
| 2028 forecast | – | 1,412 1,000–1,949 | 62% |
| 2029 forecast | – | 1,480 1,006–2,122 | 62% |
| 2030 forecast | – | 1,551 1,016–2,301 | 63% |
Deep brain and vagus nerve stimulator implants. Professional codes (what the surgeon bills): CPT 61863, 61867, 61885, 61886, 64568; the hospital bills MS-DRG 040, 041, 042.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 94% of the cases CMS names in Florida; 8 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 33% inpatient hospital, 65% hospital outpatient, 2% surgery center. The share outside the hospital has moved +2 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 18 | 941−0.6%/yr | −0.6%/yr | 0.4 | 2% | 1,460 in 2030+7.6%/yr |
| North Carolina | 8 | 293−8.9%/yr | −8.9%/yr | 0.3 | 0% | 440 in 2030+7.1%/yr |
| Virginia | 5 | 275−0.4%/yr | −0.4%/yr | 0.3 | 0% | 420 in 2030+7.4%/yr |
| Tennessee | 4 | 252+1%/yr | +1%/yr | 0.3 | 0% | 270 in 2030+1.2%/yr |
| Georgia | 3 | 211+0.2%/yr | +0.2%/yr | 0.2 | 0% | 230 in 2030+1.1%/yr |
| Kentucky | 5 | 203−3.5%/yr | −3.5%/yr | 0.4 | 0% | 330 in 2030+8.4%/yr |
| Alabama | 4 | 187−6.5%/yr | −6.5%/yr | 0.4 | 0% | 190 in 2030+0.5%/yr |
| Oklahoma | 3 | 152+4.2%/yr | +4.2%/yr | 0.3 | 0% | 150 in 2030−0.1%/yr |
| South Carolina | 2 | 151−3.2%/yr | −3.2%/yr | 0.2 | 0% | 260 in 2030+9.8%/yr |
| Louisiana | 2 | 151−6.2%/yr | −6.2%/yr | 0.4 | 0% | 1,100 in 2030+39%/yr |
| Maryland | 1 | 111−4.1%/yr | −4.1%/yr | 0.1 | 0% | 120 in 2030+1.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Aneurysm & intracranial embolization | 40 | 1,299+18%/yr | +18%/yr | 0.61.4× | 0% | 2,280 in 2030+9.8%/yr |
| Stroke thrombectomy | 32 | 1,063+2.8%/yr | +2.8%/yr | 0.51.2× | 0% | 1,080 in 2030+0.2%/yr |
| CSF shunts | 5 | 505−6.4%/yr | −6.4%/yr | 0.21.3× | 0% | 470 in 2030−1.2%/yr |
DBS & VNS in every state, and its device makers · Every procedure market in Florida · Every state · Compare with Texas
Livanova leads with 29% of company spending on these surgeons in 2025, +7 pts on 2024.
In 2025, 7 companies reported engagement with Florida’s surgeons worth $321K in consulting, speaking, meals and travel tied to these products, about $25K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 56 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.